ATE364315T1 - Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung - Google Patents

Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung

Info

Publication number
ATE364315T1
ATE364315T1 AT00928576T AT00928576T ATE364315T1 AT E364315 T1 ATE364315 T1 AT E364315T1 AT 00928576 T AT00928576 T AT 00928576T AT 00928576 T AT00928576 T AT 00928576T AT E364315 T1 ATE364315 T1 AT E364315T1
Authority
AT
Austria
Prior art keywords
tgfalpha
disclosed
tgf
functional fragments
patients undergoing
Prior art date
Application number
AT00928576T
Other languages
English (en)
Inventor
Daniel Twardzik
Stefan Paskell
Thomas Felker
Original Assignee
Applied Protein Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/299,473 external-priority patent/US20020099008A1/en
Application filed by Applied Protein Sciences Llc filed Critical Applied Protein Sciences Llc
Application granted granted Critical
Publication of ATE364315T1 publication Critical patent/ATE364315T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
AT00928576T 1999-04-26 2000-04-26 Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung ATE364315T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/299,473 US20020099008A1 (en) 1999-04-26 1999-04-26 Method for stimulating hematopoiesis using tgf-alpha
US09/459,813 US6764683B1 (en) 1999-04-26 1999-12-13 Loop peptide and TGFα for stimulating stem cell proliferation and migration

Publications (1)

Publication Number Publication Date
ATE364315T1 true ATE364315T1 (de) 2007-07-15

Family

ID=26971235

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00928576T ATE364315T1 (de) 1999-04-26 2000-04-26 Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung

Country Status (8)

Country Link
US (4) US6486122B1 (de)
EP (1) EP1176870B1 (de)
JP (1) JP2002543096A (de)
AT (1) ATE364315T1 (de)
AU (1) AU4679300A (de)
CA (1) CA2371241A1 (de)
DE (1) DE60035192T2 (de)
WO (1) WO2000065028A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL134289A0 (en) * 1997-08-04 2001-04-30 Univ California Methods for treating neurological deficits
US7795202B2 (en) 1997-08-04 2010-09-14 Neurorepair, Inc. Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a)
US20010007657A1 (en) * 1997-08-04 2001-07-12 Reid James Steven Compositions and methods for manipulating glial progenitor cells and treating neurological deficits
JP2002543841A (ja) * 1999-05-17 2002-12-24 バイオファーム ゲゼルシャフト ツア バイオテクノロジシェン エントヴィックルング ウント ツム フェルトリーブ フォン ファルマカ エムベーハー ＴＧＦ−βスーパーファミリーの新規のメンバーであるＧＤＦ―１５の神経保護特性
US20020193301A1 (en) * 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
EP1210102B1 (de) * 1999-08-19 2010-04-07 Applied Protein Sciences, LLC Tgf-alpha polypeptide, funktionelle fragmente und methoden zu deren verwendung
US7838292B1 (en) 2001-03-29 2010-11-23 University Of Louisville Research Foundation, Inc. Methods for obtaining adult human olfactory progenitor cells
EP1890722A2 (de) * 2005-05-27 2008-02-27 Five Prime Therapeutics, Inc. Verfahren und zusammensetzungen für die stimulation der glucoseaufnahme in muskelzellen, und behandlung von krankheiten
US20070031373A1 (en) * 2005-08-04 2007-02-08 Carlos Lopez Reversal of Adult Onset Disorders with Granulocyte-Colony Stimulating Factors
TW201500549A (zh) 2013-06-19 2015-01-01 Univ Taipei Medical 促進幹細胞方向性移動之方法及裝置
EP3204407A4 (de) * 2014-10-10 2018-04-04 Neurorepair Inc. Neuartige tgf-alpha-mutante proteine

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0105014B1 (de) 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Wiederherstellung von Gewebe bei Tieren
JPS6034997A (ja) 1983-05-09 1985-02-22 ジヨージ、ジヨセフ、トダロ 生物学的活性ポリペプチド類
US5240912A (en) 1983-05-09 1993-08-31 Todaro George J Transforming growth factor (TGF) peptides
US4863899A (en) 1983-05-09 1989-09-05 Todaro George J Biologically active polypeptides
EP0154434B1 (de) 1984-02-17 1993-01-27 Genentech, Inc. Menschlicher Transformationswachstumsfaktor und Vorläufer oder Fragment hiervon, Zellen, DNA, Vektoren und Verfahren zu ihrer Herstellung, Zusammensetzungen und Produkte, die diese enthalten, sowie davon abgeleitete Antikörper und Diagnostizierverfahren
US4749683A (en) 1985-01-25 1988-06-07 President And Fellows Of Harvard College Inhibition of gastric acid secretion with alpha-transforming growth factor
AU5249786A (en) * 1985-01-29 1986-08-07 Oncogen Wound healing compositions
US4686283A (en) * 1985-04-16 1987-08-11 Syntex (U.S.A.) Inc. Analogs of transforming and epidermal growth factor fragments for therapy and diagnosis
CA1275922C (en) 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
DK354487A (da) * 1986-07-11 1988-01-12 Noboru Yanaihara Oncogen-relaterede peptider
US4874746A (en) 1987-12-22 1989-10-17 Institute Of Molecular Biology, Inc. Wound headling composition of TGF-alpha and PDGF
US5658894A (en) 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5102870A (en) * 1989-04-14 1992-04-07 Schering Ag Treatment and prevention of oral mucositis with growth factors
US5182261A (en) * 1989-07-13 1993-01-26 The Rockefeller University Modified transforming growth factor alpha oligopeptides and pharmaceutical compositions thereof
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
AUPN271295A0 (en) * 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
US5229493A (en) 1990-10-26 1993-07-20 Children's Medical Center Corporation Smooth muscle mitogen
JPH04352800A (ja) 1990-10-26 1992-12-07 Childrens Medical Center Corp:The 平滑筋分裂促進因子
US5886141A (en) 1990-10-26 1999-03-23 Takeda Chemical Industries, Ltd. Smooth muscle mitogen peptides and DNA coding therefor
US5604202A (en) * 1990-11-13 1997-02-18 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of NGF growth factors to treat drug-induced neuropathy
EP0603194A4 (de) * 1991-07-05 1994-12-07 Seragen Inc Zum rezeptor des epidermalen wachstumsfaktors zielgesteuerte moleküle zur behandlung entzündlicher arthritis.
US6071889A (en) 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5980885A (en) 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
US5981165A (en) 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
AU3062392A (en) * 1991-11-04 1993-06-07 Novo Nordisk A/S Pdgf gel formulation
US6558952B1 (en) 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
US5885956A (en) 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
JP3583778B2 (ja) 1993-01-29 2004-11-04 ニューロスフィアーズ ホウルディングス リミテッド 神経幹細胞の遺伝子修飾
US5633147A (en) 1994-03-08 1997-05-27 Human Genome Sciences, Inc. Transforming growth factor αH1
GB9500660D0 (en) * 1995-01-13 1995-03-08 Secr Defence Growth factor anologs
US5840687A (en) * 1995-02-02 1998-11-24 Schering Aktiengesellschaft Modified ligands for receptor tyrosine kinases
CN1202112A (zh) 1995-11-09 1998-12-16 武田药品工业株式会社 增强胰腺功能的组合物
WO1997025349A1 (en) 1996-01-04 1997-07-17 Human Genome Sciences, Inc. Transforming growth factor alpha hiii
US5814308A (en) 1996-03-26 1998-09-29 Zhang; Ke Methods for the treatment of gastrointestinal tract disorders
JP2001504123A (ja) 1996-11-15 2001-03-27 ニューロスフェレス ホールディングス リミテッド Ｃｎｓ障害に対して保護するための成長因子を用いた予備治療
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
AU5261898A (en) 1996-12-04 1998-06-29 Abbot F. Clark Tgfalpha for the treatment of ocular hypertension and glaucoma
WO1998027210A1 (en) 1996-12-16 1998-06-25 Zymogenetics, Inc. Compositions and methods for stimulating pancreatic islet cell regeneration
IL134289A0 (en) * 1997-08-04 2001-04-30 Univ California Methods for treating neurological deficits
IL144654A0 (en) 1999-02-10 2002-05-23 Curis Inc Pancreatic progenitor cells, methods and uses related thereto
US6037357A (en) * 1999-04-21 2000-03-14 Unitech Pharmaceuticals, Inc. N-benzoyl-α-alkylated azatyrosines as anticancer agents
EP1210102B1 (de) * 1999-08-19 2010-04-07 Applied Protein Sciences, LLC Tgf-alpha polypeptide, funktionelle fragmente und methoden zu deren verwendung
US20020193301A1 (en) * 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
AU2001294647A1 (en) * 2000-09-22 2002-04-02 Stem Cell Pharmaceuticals, Inc. Method or treatment of tumors using transforming growth factor-alpha

Also Published As

Publication number Publication date
US20090068139A1 (en) 2009-03-12
US7365172B2 (en) 2008-04-29
CA2371241A1 (en) 2000-11-02
US6486122B1 (en) 2002-11-26
EP1176870A2 (de) 2002-02-06
EP1176870A4 (de) 2002-07-31
WO2000065028A2 (en) 2000-11-02
US20020169131A1 (en) 2002-11-14
EP1176870B1 (de) 2007-06-13
WO2000065028A3 (en) 2001-05-03
DE60035192T2 (de) 2008-02-14
AU4679300A (en) 2000-11-10
WO2000065028A9 (en) 2002-03-14
US20060105957A1 (en) 2006-05-18
JP2002543096A (ja) 2002-12-17
DE60035192D1 (de) 2007-07-26

Similar Documents

Publication Publication Date Title
CY1118849T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
CY1121113T1 (el) Θεραπεια της νοσου ρομρε
MA28418B1 (fr) Anticorps liant un recepteur de l'interleucine 4
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
IS7431A (is) Samrunaefnasambönd lyfja eða frumudrepandi efna og líffræðilega virkra peptíða
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
EP2357006A3 (de) Arzneimittelkonjugate und deren Verwendung zur Behandlung von Krebs, einer Autoimmunerkrankung oder einer Infektionskrankheit
WO2003049684A3 (en) Pseudo-antibody constructs
DK0910647T3 (da) Human DNase i hyperaktive varianter
PT698108E (pt) Vectores adenovirais de origem animal e utilizacao em terapia genica
DE69615561T2 (de) Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
NO20053999D0 (no) Survivin-avledede peptider og bruken av dem
TR200202231T2 (tr) Amiloidojenik hastalığın önlenmesi ve tedavisi
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
ATE364315T1 (de) Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung
BR0111182A (pt) Peptìdeos neuroprotetores
HUP0300590A2 (hu) Peptidázzal hasítható, célzott antineoplasztikus szerek és terápiás alkalmazásuk
BR9808509A (pt) Composições e métodos para o tratamento e diagnóstico do câncer de mama
DK1007566T3 (da) Terapeutisk anvendelse af SMR1-protein og aktive derivater deraf
ES2174103T3 (es) Uso de las secuencias reguladoras de wap o mmtv para expresion dirigida de genes heterologos ligados en celulas mamarias humanas, con inclusion de celulas de carcinoma mamario humano.
EP1546714A4 (de) Zusammensetzungen und verfahren zur verwendung beim abzielen auf peptide zur diagnose und therapie von krebs im menschen
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
DE60036199D1 (de) Proteaseresistente flint-analoge
DK1377320T3 (da) Polynukleotidbindingskomplekser omfattende steroler og saponiner

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties